TY - JOUR
T1 - The Effect of Neoadjuvant Therapy on Esophagectomy for cT2N0M0 Esophageal Adenocarcinoma
AU - Rodriguez-Quintero, Jorge Humberto
AU - Kamel, Mohamed K.
AU - Jindani, Rajika
AU - Elbahrawy, Mostafa
AU - Vimolratana, Marc
AU - Chudgar, Neel P.
AU - Stiles, Brendon M.
N1 - Publisher Copyright:
© 2023, Society of Surgical Oncology.
PY - 2024/1
Y1 - 2024/1
N2 - Background: For cT2N0M0 esophageal adenocarcinomas, the effects of neoadjuvant chemoradiotherapy (NT) on surgical outcomes and the oncological benefits to the patients are debatable. In this study, we investigated the optimal management for cT2N0M0 adenocarcinoma (1) assessing the perioperative impact of NT on esophagectomy and (2) evaluating the oncologic effect of NT in a homogeneous group of patients with clinical stage IIA. We hypothesized that NT does not negatively affect perioperative outcomes and provides an oncologic benefit to selected patients with cT2N0M0 disease. Methods: The National Cancer Database was queried (2010–2019) for patients with cT2N0M0 esophageal adenocarcinoma undergoing esophagectomy. After propensity-matching to adjust for differences in patient and tumor characteristics, we compared postoperative outcomes (logistic regression) and survival (Kaplan–Meier and Cox regression) among those who underwent NT vs upfront surgery (S). Results: This study included 3413 patients, of whom 2359 (69%) received NT, and 1054 (31%) S. In contrast to those who underwent S, in the matched cohort, patients treated with NT had comparable conversion rates (8% vs11.1%, p = 0.06), length of stay (9 vs 10 days, p = 0.078), unplanned readmission (5.4% vs 8.8%, p = 0.109), and 30- (3.9% vs 3.7%, p = 0.90) and 90-day mortality (5.7% vs 4.7%, p = 0.599). In addition, NT associated with improved survival in patients with cT2N0M0 tumors > 5 cm (HR 0.30, 95% CI 0.17–0.36). Conclusions: NT does not appear to increase technical complexity or to adversely affect postoperative outcomes after esophagectomy. Furthermore, minimally invasive esophagectomy is feasible following NT, with comparable conversion rates to those who had upfront surgery. Lastly, NT was selectively associated with improved survival in patients with cT2N0M0 esophageal cancer.
AB - Background: For cT2N0M0 esophageal adenocarcinomas, the effects of neoadjuvant chemoradiotherapy (NT) on surgical outcomes and the oncological benefits to the patients are debatable. In this study, we investigated the optimal management for cT2N0M0 adenocarcinoma (1) assessing the perioperative impact of NT on esophagectomy and (2) evaluating the oncologic effect of NT in a homogeneous group of patients with clinical stage IIA. We hypothesized that NT does not negatively affect perioperative outcomes and provides an oncologic benefit to selected patients with cT2N0M0 disease. Methods: The National Cancer Database was queried (2010–2019) for patients with cT2N0M0 esophageal adenocarcinoma undergoing esophagectomy. After propensity-matching to adjust for differences in patient and tumor characteristics, we compared postoperative outcomes (logistic regression) and survival (Kaplan–Meier and Cox regression) among those who underwent NT vs upfront surgery (S). Results: This study included 3413 patients, of whom 2359 (69%) received NT, and 1054 (31%) S. In contrast to those who underwent S, in the matched cohort, patients treated with NT had comparable conversion rates (8% vs11.1%, p = 0.06), length of stay (9 vs 10 days, p = 0.078), unplanned readmission (5.4% vs 8.8%, p = 0.109), and 30- (3.9% vs 3.7%, p = 0.90) and 90-day mortality (5.7% vs 4.7%, p = 0.599). In addition, NT associated with improved survival in patients with cT2N0M0 tumors > 5 cm (HR 0.30, 95% CI 0.17–0.36). Conclusions: NT does not appear to increase technical complexity or to adversely affect postoperative outcomes after esophagectomy. Furthermore, minimally invasive esophagectomy is feasible following NT, with comparable conversion rates to those who had upfront surgery. Lastly, NT was selectively associated with improved survival in patients with cT2N0M0 esophageal cancer.
KW - Esophageal adenocarcinoma
KW - Esophageal cancer
KW - Minimally invasive esophagectomy
KW - Neoadjuvant therapy
KW - Open esophagectomy
UR - http://www.scopus.com/inward/record.url?scp=85174831122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174831122&partnerID=8YFLogxK
U2 - 10.1245/s10434-023-14441-z
DO - 10.1245/s10434-023-14441-z
M3 - Article
C2 - 37884701
AN - SCOPUS:85174831122
SN - 1068-9265
VL - 31
SP - 228
EP - 238
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 1
ER -